Key insights
- Personalis CFO and COO Aaron Tachibana sold $449,292 in stock via a pre-arranged plan, coinciding with the stock trading near its 52-week high and appearing overvalued by InvestingPro analysis. While the company reported strong Q1 performance with significant growth in its NeXT Personal MRD test and expanded CMS coverage, the insider selling, even under a 10b5-1 plan, can be perceived as a bearish signal, especially given the stock's recent surge.
Aaron Tachibana, Chief Financial Officer and Chief Operating Officer of Personalis, Inc. (NASDAQ:PSNL), recently sold shares of the company’s common stock following the exercise of stock options. The transactions, which occurred on May 29, 2026, were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025.
Mr. Tachibana sold a total of 38,799 shares of Personalis common stock. These shares were sold at a weighted average price of $11.58 per share, with individual sale prices ranging from $11.50 to $11.71. The total value of the stock sold amounted to $449,292. The sale came as the stock trades near its 52-week high of $11.85, following a remarkable 146% return over the past year. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value estimate, placing it among companies on the Most Overvalued list.
Prior to the sale, Mr. Tachibana acquired 38,799 shares of common stock through the exercise of stock options at an exercise price of $9.16 per share, totaling $355,398. These options were fully vested and exercisable.
Following these transactions, Mr. Tachibana directly owns 198,833 shares of Personalis common stock. Investors seeking deeper insights can access a comprehensive Pro Research Report on PSNL, one of 1,400+ US equities covered with expert analysis and actionable intelligence on InvestingPro.
In other recent news, Personalis Inc. reported a strong first-quarter performance, surpassing revenue estimates with significant growth in its NeXT Personal minimal residual disease (MRD) test. The test saw a 258% year-over-year increase and a 26% rise quarter-over-quarter, with over 1,000 oncologists ordering it in the first quarter. Additionally, the Centers for Medicare & Medicaid Services expanded coverage for the NeXT Personal test, now including both neoadjuvant therapy monitoring for certain breast cancer patients and immunotherapy monitoring for late-stage solid tumors. These expansions mark important milestones for the company in providing broader access to its diagnostic services.
BTIG adjusted its price target for Personalis from $13 to $11, while maintaining a Buy rating, reflecting broader trends in the lab sector valuation. Meanwhile, Needham reiterated its Buy rating and set a $12 price target, highlighting the growth of the MRD test as a positive factor. In corporate governance news, Personalis held its 2026 annual stockholders meeting virtually, where shareholders approved various proposals. These developments indicate a continued focus on expanding diagnostic capabilities and maintaining investor confidence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.